TB-500 and thymosin beta-4 — what you are actually buying

Two names, historically two molecules

Thymosin beta-4 is a naturally occurring 43-residue protein. TB-500 originally referred to a shorter synthetic construct built around the actin-binding motif, which is considerably smaller. Over time the market collapsed the two names together, and today most vials labelled TB-500 contain the full-length acetylated sequence.

This matters because the two differ in mass by a factor of several. If a protocol was written against one and the vial contains the other, every concentration in the workflow is wrong by a large constant — and nothing in the appearance of the vial would tell you.

How to tell which one you have

Read the mass spectrometry figure on the COA. A result near 4963 g/mol is the full-length acetylated peptide. A result substantially lower indicates a fragment construct, whatever the label says. A COA that omits the mass entirely cannot answer the question at all, which is its own answer about the supplier.

The methionine problem

The single sulfur atom in the molecular formula is a methionine residue, and methionine is the most oxidation-prone amino acid. Oxidation adds 16 Da and typically appears as a shoulder on the leading edge of the main HPLC peak rather than as a separate peak.

Practically, this is the reason to take light and oxygen exposure seriously for this compound specifically. Purging headspace, keeping vials dark and avoiding prolonged time in solution all target this one route.

Actin sequestration, and why it is the whole mechanism

Thymosin beta-4 has a defined molecular function, which sets it apart from most compounds in this market: it binds monomeric G-actin and holds it in reserve. That regulates how much actin is available to polymerise into the filaments a cell uses to change shape and move.

This is textbook cell biology rather than a proposal. The actin-binding domain in the sequence exists to do it, and everything else attributed to the compound follows downstream. Cell migration requires actin remodelling, so a molecule governing the available actin pool is positioned to affect migration — which is what the corneal and dermal model studies in the research library measure.

Why the fragment-versus-full-length question is mechanistic

The naming confusion covered above is not only a labelling problem. The original TB-500 construct was built around the actin-binding motif specifically, on the reasoning that the motif is the functional part and the rest of the protein is scaffolding.

Full-length thymosin beta-4 carries that motif plus everything else the protein does — and a 43-residue protein interacts with more than one partner. A fragment containing only the binding motif and a full-length protein containing it among other domains are not interchangeable, whichever name a vendor prints. This is why the mass on the COA is a mechanistic question rather than a bookkeeping one.

What the methionine means for the mechanism

Oxidation of a methionine adds 16 daltons and changes the residue's chemistry. In a protein whose function depends on binding another protein, a modified residue within or near the binding interface is a functional question rather than only a purity one.

This is the practical reason peak shape matters more than the headline purity figure for this compound. An oxidised species that co-elutes sits inside a high area percent, and area percent measures how much material eluted as one peak, not whether that material still binds actin.

Handling consequences of a large, highly charged peptide

• ◆At 43 residues this is a large peptide, and large peptides adsorb to glass and plastic surfaces more readily than short ones — low-concentration solutions lose a measurable fraction to the container.
• ◆The sequence carries many charged residues, which makes it highly water-soluble and means solubility is rarely the failure mode during reconstitution.
• ◆Because the mass is high, a 5 mg vial contains far fewer moles than a 5 mg vial of a small peptide. 5 mg in 2 mL is about 0.50 mM here, against 1.76 mM for BPC-157 at the same mass and volume.

What the thymosin beta-4 literature examined

The peer-reviewed thymosin beta-4 literature includes work on actin sequestration and corneal and dermal wound models in animals. The studies indexed in the research library on this site are the primary sources; they are preclinical, and no human clinical approval exists for this compound.